3SBio Inc
HKEX:1530
Intrinsic Value
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products. [ Read More ]
The intrinsic value of one 3SBio Inc stock under the Base Case scenario is 8.83 HKD. Compared to the current market price of 6.1 HKD, 3SBio Inc is Undervalued by 31%.
Valuation Backtest
3SBio Inc
Run backtest to discover the historical profit from buying and selling 3SBio Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
3SBio Inc
Current Assets | 9.2B |
Cash & Short-Term Investments | 6B |
Receivables | 1.1B |
Other Current Assets | 2.1B |
Non-Current Assets | 14.4B |
Long-Term Investments | 3.1B |
PP&E | 5.1B |
Intangibles | 5.8B |
Other Non-Current Assets | 478m |
Current Liabilities | 3.7B |
Accounts Payable | 212.1m |
Other Current Liabilities | 3.5B |
Non-Current Liabilities | 5.9B |
Long-Term Debt | 2.7B |
Other Non-Current Liabilities | 3.1B |
Earnings Waterfall
3SBio Inc
Revenue
|
7.8B
CNY
|
Cost of Revenue
|
-1.2B
CNY
|
Gross Profit
|
6.6B
CNY
|
Operating Expenses
|
-4.1B
CNY
|
Operating Income
|
2.5B
CNY
|
Other Expenses
|
-983.5m
CNY
|
Net Income
|
1.5B
CNY
|
Free Cash Flow Analysis
3SBio Inc
Profitability Score
Profitability Due Diligence
3SBio Inc's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Score
3SBio Inc's profitability score is 63/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
3SBio Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Score
3SBio Inc's solvency score is 77/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
3SBio Inc
According to Wall Street analysts, the average 1-year price target for 3SBio Inc is 7.7 HKD with a low forecast of 6.26 HKD and a high forecast of 10.08 HKD.
Shareholder Return
Price
3SBio Inc
Average Annual Return | -9.71% |
Standard Deviation of Annual Returns | 26.01% |
Max Drawdown | -68% |
Market Capitalization | 14.6B HKD |
Shares Outstanding | 2 543 601 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
3SBio, Inc. operates as in investment holding company which engages in the development, production, marketing, and sale of biopharmaceutical products. The company is headquartered in Shenyang, Liaoning. The company went IPO on 2015-06-11. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The firm distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.
Contact
IPO
Employees
Officers
The intrinsic value of one 3SBio Inc stock under the Base Case scenario is 8.83 HKD.
Compared to the current market price of 6.1 HKD, 3SBio Inc is Undervalued by 31%.